Current Grant Funding
NCI R01 CA194158: Examination of First and Second Generation E-Cigarettes
09/30/2016 - 08/31/2021
PI: Wagener
Total Cost: $3,365,226
E-cigarettes are proliferating and evolving rapidly in the current unregulated market. To date, it is not clear how e-cigarette products in general will impact smoking behavior and downstream health outcomes, let alone the differential effects between first versus second generation e-cigarette products. The proposed work will prospectively examine the effect of switching to e-cigarettes on changes in smoking patterns, nicotine dependence, exposures to harmful toxicants and downstream physiological health effects.
NIDA U01 DA045537: Switching to the SREC: Evaluating Risk Reduction Among Quitline Treatment Failures
08/15/2018 – 07/31/2021
PI: Wagener
Total Cost: $1,489,353
E-cigarettes are proliferating and evolving rapidly. To date, it is not clear how e-cigarette products will impact health, especially among recent smoking cessation treatment failures and among priority populations for tobacco treatment (i.e., smokers with low socioeconomic status and mental health conditions), such as those served by state tobacco quitlines. The proposed work will prospectively examine the effect of switching to the NIDA SREC on changes in smoking patterns, dependence, exposures to harmful toxicants and downstream health effects.
NCI R01 CA255563: Waterpipe Tobacco Additives and Their Effect on Human Puffing Behavior, Toxicant Exposures, Pulmonary Function and Appeal
09/15/2020 – 08/31/2023
MPI: Brinkman & Wagener
Total Cost: $1,400,000
Sweet additives make up the bulk of waterpipe tobacco and have the potential to contribute to indirect harm by increasing the amount of smoke inhaled and to direct harm by degrading to form harmful and potentially harmful constituents (HPHCs) that are subsequently inhaled by the smoker. The objective of this human study is to individually quantify the harm associated with medium and high levels of the primary waterpipe tobacco additives.
NIDA R21 DA046333: Addiction and Behavior Related to Menthol Cigarette Substitutes
9/15/2018 – 08/31/2021
MPI: Wagener & Villanti
Total Cost: $427,742
The FDA has repeatedly indicated its intent to pursue a ban on menthol in cigarettes. However, estimating the impact of a potential ban on menthol in cigarettes requires accounting for likely substitutes in the marketplace that may also need to be restricted to effectively protect public health. The proposed study uses an in-laboratory and ad libitum outpatient mixed design to examine the abuse liability and substitutability of plausible menthol cigarette alternatives, including menthol filtered cigars, menthol roll-your-own cigarettes and non-menthol cigarettes, in a sample of current adult menthol cigarette smokers.
AHA 20YVNR35490079: A Comprehensive Approach to Understanding and Ending Youth E-Cigarette Addiction
07/01/2020-06/30/2022
MPI: Mohler, Wagener, Wold, Roberts & Klein
Total Cost: $5,500,000
OSUCCC Pelotonia Award: The Impact of E-Cigarette Liquid Nicotine Form on Biological Deposition of Nicotine and Cancer Risk
1/012020 – 1/01/2023
MPI: Wagener & Brinkman
Total Cost: $200,000
NCI R01 CA210625: A Naturalistic Nationwide Randomized Study of E-Cigarette Uptake and Consequences
08/01/2017 – 07/31/2022
PI: Carpenter
Electronic (e-)cigarettes are the fastest growing non-cigarette product available to smokers, yet the science base to understand these products has not kept pace. This will be among the first prospective, large scale randomized studies of e-cigarette use in the U.S., with aims to examine the naturalistic course of uptake and consequence of e-cigarette use.
NCI R01 CA242168: Biological Impact of Exclusive and Dual E-Cigarette Use on Oral Cancer Risk
07/15/2020 – 06/30/2025
PI: Queimado
Understanding the potential health effects of electronic cigarettes is of tremendous interest because (a) they are the most used tobacco product among youth and are used by over one-third of adult tobacco smokers (dual users); (b) they contain unique constituents that might have unforeseen health consequences; and (c) they might be an important tool for smoking cessation. In this proposal, we will determine how the use of electronic cigarettes by exclusive and dual users modifies DNA damage, mutation rate and gene expression — factors which increase cancer risk in humans. Our study will provide evidence-based data urgently needed by clinicians to guide their patients and by regulatory agencies to implement specific policies aiming to protect public health.
NIDA U54 DA036105: Center for the Study of Tobacco Products – Project 4
04/1/2018 – 03/31/2024
MPI: Eissenberg & Breland
NIDA R01 DA045492: Electronic Cigarettes During Pregnancy: Impact on Fetal Development
09/01/2018 – 08/31/2023
PI: Stroud
Use of electronic cigarettes has increased dramatically in the US; recent reports suggest that rates are also increasing in pregnant women. Despite known vulnerability of the developing fetus to nicotine, the impact of maternal e-cigarette use on the developing fetus is currently unknown. The proposed study addresses an urgent and unanswered public health question regarding the impact of e-cigarettes and relative impact of e-cigarettes versus conventional cigarettes on fetal development using novel two and three-dimensional ultrasonography.
NCI R01 CA229082: Optimizing Hookah Tobacco Public Education Messages to Reduce Young Adult Use
05/01/2018 – 04/30/2021
PI: Mays
Hookah (i.e., shisha, narghile, waterpipe) tobacco is one of the most commonly used tobacco products among U.S. young adults and is a growing public health concern. This study will use multiple methods to identify optimal hookah tobacco public education message content and test the impact of these messages on young adults' hookah use behaviors. The findings will be critical to inform the Food and Drug Administration's public education efforts targeting young adults' hookah tobacco use.
NIDA R21 DA042960: Enhanced E-Cigarette Coaching Intervention for Dual Users of Cigarettes and E-Cigarettes
09/01/2017 – 7/31/2021
PI: Vickerman
This project will develop and pilot test the first behavioral smoking cessation intervention for dual users of cigarettes and the Electronic Nicotine Delivery System (ENDS). If the proposed intervention ultimately proves effective, it could substantially improve the effectiveness of tobacco quitlines, make them more responsive to the changing landscape of nicotine use and increase the likelihood that the net public health impact of ENDS will be positive rather than negative.
NCI P30 CA016058: OSUCCC Cancer Center Support Grant
09/12/1997 – 11/30/2025
PI: Pollock
Role: Co-Leader, Cancer Control Program
The overall goal of the Cancer Control Program is to conduct research to reduce the incidence, mortality and morbidity of cancer in our catchment area, the state of Ohio, and beyond. The Cancer Control Program conducts research across the cancer control continuum, from etiology through survivorship, and across the lifespan. Crosscutting themes unite the aims of the program and include policy and underserved/minority populations, with a focus on the priority cancers of the OSUCCC. Our research also capitalizes on our members’ strengths, such as epidemiology, biology and behavior, and includes trans-disciplinary research teams to address research aims.